Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06062498 · ClinicalTrials.gov registry record · Phase 2

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

A Phase 2 study of Metastatic Breast Cancer and Estrogen Receptor-positive Breast Cancer, sponsored by Northwestern University.

Recruiting
Registry status
Phase 2
Development phase
174
Enrollment target
1
Study location

NCT06062498 is a Phase 2 study of Metastatic Breast Cancer and Estrogen Receptor-positive Breast Cancer that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 174 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06062498, a Phase 2 study of Metastatic Breast Cancer and Estrogen Receptor-positive Breast Cancer, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
Phase 2
Development phase
174 participants
Enrollment target
1
Study location

Study Summary

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.

Conditions Studied

Metastatic Breast Cancer Estrogen Receptor-positive Breast Cancer HER2/Neu-Negative Breast Cancer Advanced Breast Cancerv

Interventions

  • DRUG elacestrant, palbociclib, abemaciclib, ribociclib

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2023-09-29
Est. Completion 2027-07-01
Phase Phase 2

Sponsor

Northwestern University

1,209 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06062498

The ClinicalTrials.gov registry entry for NCT06062498 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (15% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which elacestrant, palbociclib, abemaciclib, ribociclib is the first listed.

NCT06062498 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06062498 about?

NCT06062498 is a clinical study titled "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer". Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nat...

What is the current status of trial NCT06062498?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2023-09-29. Estimated completion is 2027-07-01.

What conditions does trial NCT06062498 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv.

What interventions are being tested in trial NCT06062498?

The interventions under investigation include: elacestrant, palbociclib, abemaciclib, ribociclib (DRUG).

Who is sponsoring clinical trial NCT06062498?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06062498 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

Estrogen Receptor-positive Breast Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.